What hormonal workup should be performed in a reproductive‑age woman with suspected polycystic ovary syndrome, and when should it be done relative to the menstrual cycle and contraceptive use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hormonal Workup for PCOS

The hormonal workup for suspected PCOS should include early morning fasting measurements of total testosterone (TT), free testosterone (FT) or calculated free androgen index (FAI), LH, FSH, prolactin, TSH, and 17-hydroxyprogesterone (17-OHP), performed during the first 7 days of the menstrual cycle (early follicular phase) and after discontinuing hormonal contraceptives for at least 3 months. 1, 2

Timing Relative to Menstrual Cycle

Blood samples must be obtained during days 1-7 of the menstrual cycle (early follicular phase) to ensure accurate interpretation of hormone levels 1. This timing is critical because:

  • LH, FSH, and sex steroids fluctuate throughout the cycle
  • Reference ranges are established for follicular phase values
  • 17-OHP levels are most reliable when measured in the morning during the follicular phase 3

Contraceptive Use Considerations

Discontinue all hormonal contraceptives for at least 3 months before testing 4. Hormonal contraceptives significantly alter:

  • Sex hormone binding globulin (SHBG) levels
  • Free testosterone measurements
  • LH/FSH ratios
  • Overall androgen profiles

Testing while on contraceptives will yield unreliable results and may mask or falsely suggest PCOS 1.

Core Hormonal Tests

First-Line Androgen Assessment

Total testosterone (TT) is the initial screening test 3, 2:

  • Use liquid chromatography-tandem mass spectrometry (LC-MS/MS) when available for superior accuracy
  • Direct immunoassays are less reliable, particularly at the low concentrations typical in women
  • Elevated TT (>2.5 nmol/L or laboratory-specific cutoffs) suggests hyperandrogenism 5

Free testosterone (FT) or calculated FAI 2:

  • If TT is normal but clinical suspicion remains high, measure FT
  • Calculate FAI using: (Total testosterone/SHBG) × 100
  • FAI >4.26 suggests hyperandrogenemia in reproductive-age women 4
  • Free testosterone should be measured by equilibrium dialysis or calculated, NOT by direct immunoassay 2

Gonadotropins

LH and FSH 1, 6:

  • LH/FSH ratio >2.5 suggests PCOS, though only present in ~60-70% of cases
  • Elevated LH with normal/low FSH indicates ovarian dysfunction
  • Both low (<10 IU/L) suggests functional hypothalamic amenorrhea, not PCOS 6
  • Both elevated (>15 IU/L) suggests primary ovarian insufficiency, not PCOS 6

Exclusion of Mimicking Conditions

Prolactin 3, 7:

  • Exclude hyperprolactinemia, which can present with amenorrhea and hirsutism
  • Elevated prolactin requires further evaluation for pituitary adenoma

TSH (and free T4 if abnormal) 7:

  • Thyroid dysfunction commonly causes menstrual irregularity
  • Must be excluded before diagnosing PCOS

17-hydroxyprogesterone (17-OHP) 3, 1:

  • Mandatory in high-risk populations: Ashkenazi Jews (1:27 prevalence), Hispanics (1:40), Slavics (1:50)
  • Measure at 8 AM during follicular phase
  • Elevated levels (>200 ng/dL) suggest non-classic congenital adrenal hyperplasia
  • May require ACTH stimulation test for confirmation if borderline elevated 1

Second-Line Tests (When Indicated)

Androstenedione (A4) 2:

  • Consider if TT and FT are normal but clinical hyperandrogenism persists
  • Less specific than testosterone but may be elevated in PCOS
  • Levels >10.0 nmol/L warrant investigation for adrenal/ovarian tumor 5

DHEA-S 3, 1:

  • Indicates adrenal androgen contribution
  • Age 20-29: >3800 ng/mL suggests adrenal pathology
  • Age 30-39: >2700 ng/mL suggests adrenal pathology 5
  • Markedly elevated levels (>600 μg/dL) raise concern for adrenal tumor 6

Anti-Müllerian hormone (AMH) 6, 8:

  • May support PCOS diagnosis in adults (often elevated)
  • NOT recommended for diagnosis in adolescents due to overlap with normal pubertal values 8, 9

Metabolic Screening (Part of Initial Workup)

Fasting glucose and insulin 5:

  • Fasting glucose >7.8 mmol/L suggests diabetes
  • Glucose/insulin ratio <4 suggests insulin resistance
  • Essential for risk stratification in PCOS

Critical Pitfalls to Avoid

  1. Testing during the wrong cycle phase renders results uninterpretable—always confirm follicular phase timing
  2. Using direct immunoassays for free testosterone produces unreliable results; insist on calculated values or equilibrium dialysis 2
  3. Testing while on hormonal contraceptives will suppress androgens and alter SHBG, masking the diagnosis
  4. Relying on a single elevated androgen without excluding other causes (pregnancy, thyroid disease, hyperprolactinemia, CAH)
  5. Assuming normal TT excludes PCOS—measure free testosterone or FAI if clinical suspicion is high 3
  6. Using polycystic ovarian morphology alone in adolescents—this is physiologically normal during puberty 7, 9

Laboratory Quality Considerations

Use a reliable specialty laboratory with:

  • Established proficiency in androgen measurement
  • LC-MS/MS capability for testosterone assays
  • Validated reference ranges for reproductive-age women
  • Quality control ensuring stable values over time 1

Many commercial laboratories provide inaccurate testosterone measurements and inappropriate reference ranges, leading to misdiagnosis 1.

Special Population: Adolescents

In adolescents, diagnosis requires persistent evidence (>2 years post-menarche) of both 7, 9:

  • Irregular menstrual cycles (oligomenorrhea defined as cycles >45 days or <8 cycles/year)
  • Clinical or biochemical hyperandrogenism

Do not use polycystic ovarian morphology or AMH for diagnosis in adolescents, as these overlap with normal pubertal development 8, 9.

References

Guideline

american association of clinical endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2001

Guideline

reproductive dysfunction in women with epilepsy: recommendations for evaluation and management.

Journal of Neurology, Neurosurgery and Psychiatry, 2002

Guideline

functional hypothalamic amenorrhea: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.